Brief: Shield Therapeutics Plc H1 Group Revenues $21.4 Mln
21/08/2025 14:34
Aug 21 (Reuters) - Shield Therapeutics PLC STXS.L: SHIELD THERAPEUTICS PLC - ON TRACK FOR CASH FLOW POSITIVE 2025 SHIELD THERAPEUTICS PLC: H1 GROUP REVENUES $21.4 MILLION Source text: ID:nRSU2993Wa Further company coverage: STXS.L ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update